Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome. Pacritinib (SB1518) is a tyrosine kinase inhibitor (TKI) with equipotent activity...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2011
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3256753/
https://ncbi.nlm.nih.gov/pubmed/22829080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2011.43
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky